U.S. COMPANY FILING
PFIZER INC — Form 10-Q filed 2026-05-05
Filing text preview
Pfizer's Q1 2026 revenue rose 5.4% to $14.45B, but net income fell 9.4% to $2.69B. The company exited its ViiV investment for $1.875B cash and signed a China commercialization deal for ecnoglutide. Restructuring costs decreased significantly.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record